2024-09-25 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

This report analyzes Abbott Laboratories (ABT) stock based on the provided data.

**1. Performance Comparison:**

* **Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics. 
* **Cumulative Return:** ABT's cumulative return is 104.02% compared to S&P 500 (VOO) at 133.37%.
* **Performance Gap:** ABT has underperformed the S&P 500 by -29.35%, which is 13.23% of the historical range of performance gaps between ABT and VOO (ranging from -46.17% to 65.94%).

**2. Recent Price Movements:**

* **Closing Price:** $113.68
* **5-day Moving Average:** $114.12
* **20-day Moving Average:** $114.86
* **60-day Moving Average:** $109.45
* **Analysis:** The stock is trading slightly below its 5-day and 20-day moving averages, indicating short-term weakness. The 60-day moving average is below the current price, suggesting a longer-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 47.49 -  Neutral reading, indicating neither overbought nor oversold conditions.
* **PPO:** -0.47 -  Negative reading, suggesting a bearish trend.
* **Delta_Previous_Relative_Divergence:** -2.13 - Indicates a recent short-term downward trend in the stock's relative performance.
* **Expected Return:** 0.0% - The maximum expected return over the next 5 years based on current investment amount. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

* **Analysis:** The most recent earnings for Q2 2024 were reported on July 31st, with EPS of $0.74 and revenue of $10.38 billion.  These results exceeded analyst expectations. Abbott continues to demonstrate steady growth, driven by its diversified product portfolio and strong market position.

**5. News and Recent Events:**

* **Recent Market Outlook:** While the market is currently volatile due to macroeconomic factors, Abbott's strong fundamentals and consistent performance have provided some stability. Its focus on healthcare innovation and expansion in emerging markets is expected to drive future growth.
* **Analyst Opinions:**  Analysts remain optimistic about Abbott's long-term growth potential, citing its robust product pipeline and strong brand recognition.
* **Performance Highlights:**  Abbott has consistently outperformed its peers in the healthcare sector.  Its recent acquisition of Alcon, a leading ophthalmic device company, is expected to further strengthen its position in the market.

**6. Overall Analysis:**

Abbott Laboratories is a well-established healthcare company with a diversified business model and a strong track record of growth. While its recent performance has lagged behind the S&P 500, its solid fundamentals and positive market outlook suggest potential for future growth. Its recent earnings beat expectations and the company is making strategic investments to strengthen its position in the healthcare market. Investors should monitor the company's progress on its key initiatives, including the integration of Alcon and the development of innovative new products.

**7. Investment Recommendations:**

* **Long-Term Growth:**  ABT presents an opportunity for long-term investors seeking exposure to the healthcare sector. Its consistent performance and diversified product portfolio suggest the potential for continued growth.
* **Defensive Play:** ABT can serve as a defensive play in a volatile market, providing stability due to its essential healthcare products and services. 
* **Consider Risk Tolerance:**  While ABT has a history of stability, it's essential to consider individual risk tolerance before investing. 

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. It's crucial to conduct thorough research and consult with a financial professional before making any investment decisions. 
